Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma

Author:

Chamie Karim1,Donin Nicholas M.2,Klöpfer Pia3,Bevan Paul4,Fall Barbara5,Wilhelm Olaf5,Störkel Stephan6,Said Jonathan7,Gambla Michael8,Hawkins Robert E.9,Jankilevich Gustavo10,Kapoor Anil11,Kopyltsov Evgeny12,Staehler Michael13,Taari Kimmo14,Wainstein Alberto J. A.15,Pantuck Allan J.1,Belldegrun Arie S.1

Affiliation:

1. Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles

2. Department of Urology, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles

3. Wilex AG, Munich, Germany5MorphoSys AG, Munich, Germany

4. Wilex AG, Munich, Germany

5. Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany

6. Institute of Pathology, University of Witten/Herdeke and Helios Hospital, Wuppertal, Germany

7. Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles

8. Central Ohio Urology Group, Columbus

9. Christie Hospital NHS Trust, University of Manchester, Manchester, England

10. Clinical Oncology, Carlos G Durand Hospital, Buenos Aires, Argentina

11. Department of Clinical Oncology, McMaster University, Hamilton, Ontario, Canada

12. State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia

13. Department of Urology, University Hospitals Munich, Campus Grosshadern, Munich, Germany

14. Department of Urology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland

15. Faculty of Medical Sciences of Minas Gerais (FELUMA), Belo Horizonte, Brazil

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 114 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3